)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Krystal Biotech
Krystal Biotech (KRYS) investor relations material
Krystal Biotech Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary2 Nov, 2026
Executive summary
Q3 VYJUVEK revenue rose 30% YoY to $127.3M; diluted EPS was $2.05 and operating income increased 72% to $71.1M.
Cumulative VYJUVEK net revenue since launch reached $1,093.3M; cash, cash equivalents and investments totaled $1,194.2M at September 30, 2026.
Pipeline advanced across dermatology, ophthalmology, respiratory disease and oncology; a $400M share repurchase program was authorized.
Financial highlights
Q3 net product revenue was $127.3M vs. $97.8M; 9M revenue was $362.9M vs. $282.0M, up 29%.
Q3 operating income was $71.1M vs. $41.4M; net income was $63.1M vs. $79.4M. 9M net income was $173.8M vs. $153.4M.
Q3 R&D expense was $14.9M vs. $14.6M; SG&A was $33.7M vs. $37.6M, including $3.0M of litigation-cost insurance proceeds.
9M operating cash flow was $246.4M vs. $123.4M; cash and cash equivalents were $462.8M at quarter-end.
FY 2026 non-GAAP combined R&D and SG&A guidance was reduced to $155M-$165M, excluding stock-based compensation.
Outlook and guidance
Italy launch is expected in early 2027; a Spain pricing decision is expected before year-end 2026, while France negotiations may continue into 2027.
KB803 IOLITE last-patient visit is expected in February 2027, with top-line results shortly afterward; KB801 EMERALD-1 enrollment completion and results are expected in 2027.
KB407 repeat-dose interim results are expected in H1 2027, with a registrational study targeted for 2027; KB408 interim results are expected in 2027.
KB111 HALITE-1 interim results are expected before year-end 2026; an FDA meeting is expected in Q1 2027, with a registrational study targeted later in 2027.
KYANITE-1 aims to enroll 70 patients at the selected KB707-plus-chemotherapy regimen by mid-2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Krystal Biotech
- Strong revenue growth and late-stage pipeline advances position for continued expansion.KRYS
Corporate presentation - Q2 2026 revenue rose 24% to $119.2M, with 95% gross margin and strong global expansion.KRYSQ2 2026
- Robust revenue, global expansion, and a deep gene therapy pipeline drive growth and innovation.KRYSCorporate presentation
- Global expansion and pivotal pipeline progress set the stage for a transformative 12-24 months.KRYSBank of America Global Healthcare Conference 2026
- All proposals, including director elections and compensation policies, were approved.KRYSAGM 2026
- Q1 2026 revenue and profit surged, with strong margins and major clinical milestones ahead.KRYSQ1 2026
- KB407 achieved robust, safe CFTR delivery and expression in CF lungs, enabling registrational trials.KRYSStudy Update
- KB408 and KB407 show strong safety, efficient lung gene delivery, and support for accelerated development.KRYSStatus Update
- KB301 showed durable, meaningful wrinkle reduction and safety, advancing to Phase 2 for décolleté.KRYSStudy Result
Next Krystal Biotech earnings date
Q4 202616 Feb, 2027
Krystal Biotech
Next Krystal Biotech earnings date
Q4 202616 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Krystal Biotech Inc., known as Krystal Biotech, is a biotechnology firm engaged in the development and commercialization of genetic medicines targeting rare and serious diseases. The company focuses on creating treatments using gene therapy approaches, with a significant emphasis on dermatological conditions. Its product pipeline includes innovative therapies such as bercolagene telserpavec (B-VEC) for dystrophic epidermolysis bullosa, a severe skin disorder, and other treatments targeting conditions like autosomal recessive congenital ichthyosis and aesthetic skin conditions. Utilizing its proprietary skin TARgeted Delivery (STAR-D) platform, Krystal Biotech aims to advance treatments for various skin diseases, leveraging gene therapy's potential to offer long-term solutions. The company is headquartered in Pittsburgh, Pennsylvania, and its shares are listed on the NASDAQ under the ticker symbol KRYS.